Maze Therapeutics (NASDAQ:MAZE) Insider Atul Dandekar Sells 7,500 Shares of Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Atul Dandekar sold 7,500 shares of the stock in a transaction on Monday, June 29th. The shares were sold at an average price of $28.02, for a total value of $210,150.00. Following the sale, the insider owned 26,250 shares in the company, valued at approximately $735,525. This trade represents a 22.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Atul Dandekar also recently made the following trade(s):

• On Wednesday, April 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The stock was sold at an average price of $25.37, for a total value of $190,275.00.

Maze Therapeutics Stock Down 0.1%

Shares of NASDAQ:MAZE opened at $29.81 on Thursday. The company has a quick ratio of 17.88, a current ratio of 17.88 and a debt-to-equity ratio of 0.11. Maze Therapeutics, Inc. has a 52-week low of $10.98 and a 52-week high of $53.65. The stock’s fifty day simple moving average is $25.81 and its 200-day simple moving average is $35.73. The company has a market capitalization of $1.65 billion, a P/E ratio of -11.78 and a beta of 2.14.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The company had revenue of $20.00 million during the quarter. As a group, equities research analysts forecast that Maze Therapeutics, Inc. will post -2.73 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on MAZE shares. Mizuho raised shares of Maze Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 11th. Truist Financial decreased their target price on shares of Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a research report on Tuesday, April 14th. BTIG Research reiterated a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a report on Wednesday, March 25th. Wedbush increased their price target on Maze Therapeutics from $43.00 to $58.00 and gave the stock an “outperform” rating in a research note on Monday, March 16th. Finally, JPMorgan Chase & Co. raised their price objective on Maze Therapeutics from $52.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, March 31st. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $66.00.

Institutional Investors Weigh In On Maze Therapeutics

Institutional investors have recently bought and sold shares of the stock. Washington University increased its holdings in shares of Maze Therapeutics by 33.3% during the 4th quarter. Washington University now owns 280,802 shares of the company’s stock worth $11,634,000 after buying an additional 70,121 shares during the last quarter. Mass General Brigham Inc purchased a new stake in Maze Therapeutics during the fourth quarter valued at about $9,943,000. ArrowMark Colorado Holdings LLC acquired a new stake in Maze Therapeutics during the third quarter worth about $14,135,000. Boothbay Fund Management LLC increased its stake in Maze Therapeutics by 365.9% during the third quarter. Boothbay Fund Management LLC now owns 351,875 shares of the company’s stock worth $9,124,000 after acquiring an additional 276,345 shares during the last quarter. Finally, Seven Grand Managers LLC purchased a new position in shares of Maze Therapeutics in the 4th quarter worth about $2,072,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.